Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

CAM314 randomized Phase 3 clinical trial results released

CAM314 randomized Phase 3 clinical trial results released

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

PharmAthene presents Protexia clinical trial results at PHEMCE conference

PharmAthene presents Protexia clinical trial results at PHEMCE conference

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

PharmAthene's Valortim demonstrates potential for anthrax treatment

PharmAthene's Valortim demonstrates potential for anthrax treatment

New data from PharmAthene's anthrax vaccine program presented

New data from PharmAthene's anthrax vaccine program presented

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Kyto advancing with a program for humanization of the mAbTCR23 antibody

BioMed Realty Trust receives additional space at Landmark under new lease agreement

BioMed Realty Trust receives additional space at Landmark under new lease agreement

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial

Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.